The Right Rebate Act would give the U.S. Department of Health andHuman Services (HHS) the ability to fine companies that knowinglymisclassify drugs in the future. (Photo: Shutterstock)
Last month, Senators Chuck Grassley (R-Iowa) and Ron Wyden(D-Ore.) introduced new legislation to ensure that drugcompanies play by the rules of the Medicaid program. The bill isaimed at preventing drug companies from overcharging Medicaid, a practice that has beenconsistently costing taxpayers billions of dollars. While thelegislation is an excellent indicator of future bipartisan cooperation on the issue ofprescription drug affordability, much more needs to be done.
Grassley and Wyden's new bill, the Right Rebate Act, would givethe U.S. Department of Health and Human Services (HHS) the abilityto fine companies that knowingly misclassify drugs in the future.It would also give HHS the ability to directly adjust a drug'sclassification. The issue stems from drugs being misclassified bymanufacturers as generic when they should be classified as brandname.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
